Altered skeletal muscle lipid metabolism is a hallmark feature of type 2 diabetes (T2D). Here we investigated muscle lipid turnover in T2D versus BMI-matched controls and examined if putative in vivo differences would be preserved in the myotubes.
Introduction
Perturbations in lipid metabolism are associated with insulin resistance and type 2 diabetes (T2D) (1) . It has been proposed that an increased lipid supply, altered lipid partitioning and a reduced capacity for skeletal muscle fat oxidation could contribute to intramyocellular lipid (IMCL) accumulation, lipotoxicity and insulin resistance (2) (3) (4) . However, whether these are inherited characteristics of T2D, or simply the consequence of altered lifestyle and obesity, remains an ongoing debate. In that context, studies in human primary myotubes are of interest, as cell autonomous models are devoid of direct environmental influences. Using such a model, Hulver et al. (5) demonstrated that myotubes of non-diabetic severely obese individuals retained abnormal lipid partitioning (i.e. elevated triacylglycerol to blunted fatty acid oxidation ratio; TAG/FAO) (5) . Interestingly, Aguer et al. (6) showed that T2D subjects had increased IMCL content in muscle tissue, and that this elevation was maintained in primary myotubes from these subjects when compared with obese non-diabetic controls, indicating that increased IMCL content is preserved in vitro. However, the underlying reason for this was not examined.
Elevated FA uptake could contribute to an increased IMCL content observed in obesity and T2D.
Some studies show no difference in uptake of FAs (7; 8) , while others show increased FA uptake in skeletal muscle of obese and T2D individuals (9) . Likewise, studies in primary human myotubes also showed inconsistent results (6; 10; 11). Taken together, it is unclear whether disturbances that exist in skeletal muscle tissue lipid metabolism of T2D individuals are preserved in the myotubes. If these disturbances do persist in the myotubes, are they related to any aspects of the in vivo metabolic phenotype of the donors themselves?
As aberrant lipid metabolism is a central feature of obesity and T2D, the goal of the present study was to investigate whether disturbances exist in intramyocellular FA metabolism in
Page 3 of 37 Diabetes
Muscle lipid incorporation is retained in vitro 4 skeletal muscle of obese T2D individuals compared with BMI-and age-matched normoglycemic controls and to examine whether disturbances in lipid metabolism are retained in vitro in the myotubes established from these donors. Our study is a unique combination of ex vivo and in vitro analyses of lipid metabolism in human skeletal muscle, coupled with detailed in vivo clinical phenotyping to assess insulin sensitivity and aerobic capacity. We measured ex vivo FA metabolism in skeletal muscle tissue and established primary myotubes from these donors for in vitro studies. For comparison, we measured FA metabolism in skeletal muscle tissue of young, lean males. The myotubes were used to investigate lipid turnover (FA uptake, oxidation and storage) using two different long-chain FAs. We show that FA incorporation into triacylglycerol (TAG) is impaired in T2D muscle and in the myotubes established from these T2D donors,
indicating that this perturbation is inherent to the T2D muscle cell.
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Research Design and Methods
Participants. Twelve obese males with type 2 diabetes (T2D, n=6) and BMI-and age-matched males (Control) participated. Participants with T2D were diagnosed at least 1 year prior to the study, non-insulin dependent, had well-controlled diabetes (HbA1c < 7.8%; 62mmol/mol; 177 mg/dL) and no diabetes-related co-morbidities. Medication use (Metformin only or Metformin plus sulfonylureas) was stable for at least 6 months. Control participants had no family history of diabetes. We included data from 16 young, lean males that participated in another (unpublished) study. The studies were approved by the Medical Ethical Committee of Maastricht University.
All participants gave written informed consent, performed a maximal aerobic capacity test (VO 2 max) (12) and underwent DXA or hydrostatic weighing for body composition (13) .
Hyperinsulinemic-euglycemic clamp. To measure peripheral insulin sensitivity, a two-step hyperinsulinemic-euglycemic clamp was performed according to DeFronzo et al. (14) . Briefly, after an overnight fast, a blood sample was drawn to measure glucose, insulin and free fatty acids (FAs).
Step 1 was initiated with an insulin infusion at 10mU/m 2 /min for 4h with variable coinfusion of 20% glucose.
Step 2 consisted of a 2h insulin infusion at 40mU/m 2 /min (20% variable glucose). The M-value was calculated as the glucose infusion rate and corrected for fatfree mass (FFM).
Muscle biopsy. Muscle biopsies were taken from the vastus lateralis according to Bergström (15) and processed same day for ex vivo assays and cell culture. Remaining tissue was stored at -80°C for future analyses.
Primary muscle cell cultures. Primary skeletal muscle cell cultures were established as previously described (16) . Briefly, satellite cells were isolated and grown in media supplemented with 16% Fetal Bovine Serum (FBS) at 37°C, 5%CO 2 .
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Real Time quantitative RT-PCR. Total RNA was isolated from ~20mg of muscle tissue as previously described (17) . Primers and probes are shown in Supplemental Table 3 . Real Time qRT-PCR were performed as one-step reactions (18) as previously described (19) . All expression data were normalized by dividing the target gene by the internal control gene.
Western blots. Western blots were performed using antibodies directed against PLIN2 and PLIN5 (Progen, Germany), PLIN3 (Santa Cruz, Germany), ATGL (Cell Signaling, USA), and sr-actin (Sigma, USA). We were unable to detect PLIN2 in myotubes. Secondary antibodies contained a fluorescent tag (IRdye). Protein quantification was performed on an Odyssey
Infrared Imaging system (LI-COR Biotechnology, USA).
Oil-red-O staining. Fresh muscle cryosections were stained for IMCL by Oil-Red-O as described previously (20) In vitro triacylglycerol levels. Intracellular triacylglycerol levels in differentiated myotubes were measured using the method of Schwartz and Wolins (24) .
DGAT activity assay. Determination of DGAT activity was performed in cellular homogenates of the human myotubes as previously described (25 
Page 8 of 37 Diabetes
Results
In vivo
Clinical characteristics of individuals with type 2 diabetes, obese controls and young, lean subjects Clinical characteristics are presented in Table 1 . By definition, fasting plasma glucose levels were significantly higher in individuals with T2D compared with obese controls (C) (C: 5. 
Ex vivo
Intramuscular lipid content, fiber type and fatty acid metabolism Intramuscular lipid content (IMCL) was similar between obese controls and T2D ( Figure 1 ). We then investigated fatty acid oxidation rates in skeletal muscle homogenates using an exogenously supplied long-chain fatty acid (LCFA; 14 C-palmitate). Palmitate oxidation to 14 CO 2 ("complete oxidation") was significantly reduced in individuals with T2D (C: 0.099 ± 0.017, T2D: 0.053 ± 0.007nmol/mg protein, P=0.03; Figure 2A ). Acid-soluble metabolites (ASMs; "incomplete oxidation") were not different between the two groups (P=0.86; Figure 2B ). Thus, the ratio of complete to incomplete oxidation (CO 2 :ASMs), which is indicative of a more efficient FA metabolism, was also reduced in the T2D group (C: 0.12 ± 0.01, T2D: 0.07 ± 0.01, P<0.01; Figure 2C ). The ratio of palmitate CO 2 :ASMs trended to correlate positively with VO 2 max (r=0.537, P=0.072) and inversely with fasting plasma glucose levels (r=-0.566, P=0.055) (Supplemental Figure 1) . The same measurements performed in skeletal muscle tissue from young, lean subjects revealed significantly higher "complete" oxidation compared with both groups (Figures 2A-C) .
We next measured the incorporation of 14 C-palmitate into lipids in skeletal muscle homogenates.
While incorporation of 14 C-palmitate into the total lipid pool was similar between the two groups ( Figure 2D ), we did observe decreased incorporation of 
In vitro
Exogenous fatty acid metabolism
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In contrast to 14 C-palmitate oxidation in muscle homogenates, in vitro 14 C-palmitate oxidation to CO 2 was not significantly lower in individuals with T2D (P=0.38; Figure 3A ). Furthermore, oxidation to ASMs was not significantly different (P=0.59; Figure 3B ), and consequently neither was the ratio of CO 2 to ASMs (P=0.38; Figure 3C ). Moreover, in vitro 14 C-palmitate oxidation to CO 2 did not correlate with the ex vivo 14 C-palmitate oxidation (P=0.721; data not shown),
suggesting that the capacity to oxidize palmitate to CO 2 is not an intrinsic property of the myotubes established from these obese T2D and non-diabetic individuals.
14 C-palmitate incorporation into the total lipid pool was lower in myotubes established from individuals with T2D (C: 5.84 ± 1.46, T2D: 3.28 ± 0.27nmol/mg protein, P=0.058; Figure 3D ).
Similarly, 14 C-palmitate incorporation into TAG trended to be reduced in T2D myotubes (P=0.085; Figure 3E ); however, DAGs (P=0.145; Figure 3F ) were not significantly lower in individuals with T2D. In vitro 14 C-palmitate incorporation into TAG strongly correlated with ex vivo 14 C-palmitate incorporation into TAG (r=0.848, P=0.008; data not shown). We next determined 14 C-palmitate uptake and DGAT activity in primary myotubes to investigate if a reduced FA uptake and/or reduced enzymatic activity might underlie the reduced incorporation of FAs into TAG. Palmitate uptake (P=0.85; Figure 3G ) and DGAT activity (C: 9.28 ± 0.92, T2D: 7.69 ± 1.17nmol/h/mg protein, P=0.31; Figure 3H ) did not significantly differ between groups.
Endogenous fatty acid metabolism It has been suggested that endogenous, rather than exogenous, IMCL oxidation is reduced in myotubes from obese or obese T2D subjects compared with lean subjects (27) . Therefore, we examined 14 C-oleate oxidation after a 24h pulse with 500µM oleate (in the absence of carnitine to label the endogenous lipid pool). Oleate was chosen instead of palmitate because of the Figure 4A ). Furthermore, 14 C-oleate incorporation into TAG was significantly lower in myotubes from individuals with T2D (C: 2.24 ± 0.47, T2D: 0.94 ± 0.25nmol/mg protein, P=0.03; Figure 4B ). 14 C-oleate incorporation into DAG was not significantly different between the two groups (P=0.31; Figure 4C ).
Following a 24h incubation with 14 C-oleate, oxidation was initiated by addition of carnitine and measured after 3 hours. Interestingly, even despite a reduced 14 C-oleate incorporation into TAG in myotubes from individuals with T2D, the oxidation of endogenous 14 C-oleate to CO 2 was not significantly different between the groups (P=0.384; Figure 4D ). Likewise, oxidation to ASMs was similar between the two groups (C: 0.070 ± 0.012, T2D: 0.058 ± 0.015nmol/mg protein, P=0.543; Figure 4E ). Consequently, no differences were observed in the ratio of CO 2 to ASMs (P=0.49; Figure 4F ). Thus, in concert with the oxidation rates of exogenous 14 C-palmitate, oxidation of the endogenously labeled 14 C-oleate pool was similar in primary myotubes from both groups.
Of interest, in vivo basal glucose concentration was inversely related to in vitro incorporation of the endogenously-labeled lipid [ 14 C-oleate] into the total lipid pool (r=-0.615, P=0.033, Figure   5A ), as well as TAG (r=-0.580, P=0.048, Figure 5B ). Insulin sensitivity was also positively associated with 14 C-oleate incorporation in the total lipid pool (r=0.602, P=0.038, Figure 5C ).
It is important to note that there was no difference in the basal myocellular lipid content between the two donor groups, and thus no label dilution effect on the metabolic assays (data not shown).
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Finally, we measured the expressions of the lipid droplet coat proteins, PLIN5 and PLIN3, as well as the lipolytic protein ATGL before and after 24 hours of a 400µM oleate load ( Figures   6E-G) . We were unable to detect PLIN2 protein in the myotubes. In contrast to the ex vivo findings, PLIN5 was not different between the groups in the basal condition. However, PLIN5 trended to increase with the fatty acid load in the control group only (C, P=0.073 vs. T2D, P=0.468; Figure 6E ). PLIN3 and ATGL protein expressions were not different between groups in the basal condition, nor did they significantly change in response to the oleate load ( Figure 6F -G). Interestingly, PLIN5 protein (post-oleate load) was significantly associated with M-value at 40mU of insulin (r=0.61, P=0.035; data not shown). We further examined if differences between groups were present in mRNA expression of genes involved in lipid metabolism (Supplemental Table 1 ) in skeletal muscle tissue and/or primary myotubes. Although no significant differences were observed, PGC1α mRNA was significantly associated with increased palmitate and oleate incorporation into TAG in the myotubes, as well as DGAT activity; while PGC1α mRNA in the muscle tissue was significantly associated with tissue PLIN5 mRNA (Supplemental Table 2 ). 
Page 14 of 37 Diabetes
We show a blunted "complete" oxidation of palmitate in the skeletal muscle tissue of obese individuals with T2D compared with their BMI-matched controls and young, lean subjects. As there were no differences in the acid-soluble metabolites (ASMs), the ratio of complete to incomplete oxidation was also reduced in T2Ds. These findings extend those of Hulver et al., who demonstrated aberrant exogenous FA oxidation in the skeletal muscle of obese and severely obese (BMI, 53.8 ± 3.5 kg/m 2 ) individuals compared with lean controls (43) . In this context, our data imply that T2D is associated with reduced tissue FA oxidation independent of BMI.
Interestingly though, we did not observe significant differences in oxidation of exogenous palmitate to CO 2 and ASMs between myotubes of obese individuals with T2D and their BMImatched controls. We then examined if FA oxidation from endogenous lipid pools was compromised in the myotubes of these individuals with T2D. After an overnight loading of the myotube lipid pool with oleate, no differences in endogenous FA oxidation rates between obese and T2D myotubes were observed. This contrasts with the findings of Gaster et al. (27) who demonstrated that complete oxidation of endogenous, but not exogenous, FAs was reduced in T2D myotubes compared with obese controls. One major difference between our studies and those of Gaster et al. is that in our studies we included subjects that were marginally obese (although all had a BMI >30 kg/m 2 ), resulting in a lower average BMI compared with the previous study by Gaster et al. (27) . Another potential explanation is that these two studies compare distinct subgroups of the obese population that may have been exposed to different environmental factors which could uniquely impact a varied genetic or epigenetic background.
Our data suggest that a reduced myocellular fat oxidative capacity in individuals with T2D may not be an intrinsic characteristic, but rather a consequence of their environment.
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It was recently shown that one bout of exercise improves the capacity to store TAG in muscle and thereby prevents lipid-induced insulin resistance (42) . Moreover, by use of in vivo infusion The reason for the retained aberrant lipid incorporation capacity in T2D is so far unknown. We investigated if skeletal muscle FA uptake may underlie these findings. Skeletal muscle FA uptake is a controversial topic, with some investigators finding no difference in uptake of FAs (7; 45), while others show increased FA uptake in skeletal muscle of obese and T2D individuals (9).
Here we could not detect differences in short-term FA uptake rates in cultured myotubes of individuals with T2D compared with BMI-matched controls. Reduced TAG incorporation in the may not yet be associated with insulin resistance and T2D. In addition, we could not detect differences in mRNA levels of lipid metabolism genes, nor in enzymatic activity of DGAT, between T2D and obese controls. However, we did observe significantly positive associations of PGC1α mRNA with DGAT activity and the capacity to incorporate both palmitate and oleate into TAG in the myotubes. These relationships support our previous findings that highlight the role of PGC1α in the regulation of intramuscular lipid droplet programming in mice and humans (47) . Finally, we focused on expression levels of the lipid droplet coat proteins PLIN5, PLIN3
and PLIN2, as well as the lipolytic protein ATGL, in both muscle tissue and myotubes because we previously showed in animal studies that overexpressing PLIN2 or PLIN5 increases TAG storage capacity and results in prevention from high-fat induced insulin resistance (40; 48). Here we found that PLIN5 was elevated in the muscle tissue of the T2D individuals, but not in the myotubes. This is surprising given that the tissue lipid levels were not different between the two groups, and that PLIN5 has been associated with insulin sensitivity in humans (38) . However, PLIN5 protein expression was not different between the two groups of myotubes in the basal state, which is in line with the similar lipid levels observed in these myotubes. Moreover, PLIN5 protein levels increased after an overnight oleate load in the BMI-matched myotubes, but not in those myotubes derived from T2D individuals. These data are consistent with the increased neutral lipid and TAG storage observed in these myotubes from the BMI-matched controls. In support of the notion that an increased TAG storage capacity is protective against the development of insulin resistance in conditions of increased lipid supply, we demonstrate that PLIN5 protein levels (post-oleate load) in the myotubes were positively related to insulin 
Statement of Justification
These Supplemental Materials are pertinent to providing additional information in the form of data tables and figures that enhance the understanding of the manuscript as a whole.
Supplemental Figure 1 . Correlation of the ratio 14 C-palmitate oxidation to CO 2 :ASMs with (A) the VO 2 max and (B) the fasting plasma glucose levels in obese individuals with T2D and BMImatched controls. Due to formatting, Supplemental Table 3 is in a separate file.
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